Prevenar 13®
(pneumococcal polysaccharide conjugate vaccine)

What is Prevenar 13 and what is it used for?

Prevenar 13 is a conjugate vaccine that helps provide protection against 13 serotypes of the bacterium, Streptococcus pneumoniae; a bacterium responsible for causing infection which can be grouped into categories of invasive and non invasive disease. Invasive disease includes both meningitis (infection of the membranes around the brain and spinal cord) or bacteraemia (blood infection). Non invasive disease is when the bacterium causes pneumonia (an infection of the lungs) or otitis media (infection of the middle ear).

Prevenar 13 may be given to adults, adolescents and infants over the age of 6 weeks.

Prevenar 13 will only protect against the 13 serotypes contained within the vaccine. As with all vaccines, Prevenar 13 may not protect everyone who is fully vaccinated.

 

When should the vaccine be administered?

Prevenar 13 is indicated for active immunisation of individuals from the age of 6 weeks and should be used in accordance with official available recommendations.

The medicine can only be obtained with a prescription.

 

Reference Information

The European Medicines Agency (EMA) is an agency of the European Union (EU). The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See what guidance they offer about Prevenar 13.

Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.

If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Prevenar 13 please follow these links:

 

Great Britain
Prevenar 13® (pneumococcal polysaccharide conjugate vaccine)

Northern Ireland
Prevenar 13® (pneumococcal polysaccharide conjugate vaccine)

 

 

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.

PP-PRE-GBR-0027 / October 2021